Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.52 |
| ▸ | PRSS1 | P07477 | 6/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | PLG | P00747 | 1/20 | 0.48 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.48 |
| ▸ | C1S | P09871 | 1/20 | 0.48 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9565397 | 0.92 | KMT2A (0.54) | KMT2ASMPD1PRSS1THRBNR1H4 | |
| SCHEMBL30785561 | 0.92 | KMT2A (0.54) | KMT2ASMPD1PRSS1THRBNR1H4 | |
| SCHEMBL11422303 | 0.87 | PRSS1 (0.60) | KMT2ASMPD1PRSS1THRB | |
| SCHEMBL5202638 | 0.86 | KMT2A (0.62) | KMT2ASMPD1THRBNR1H4MAPK1 | |
| SCHEMBL2934559 | 0.86 | KMT2A (0.71) | KMT2ASMPD1PRSS1NR1H4KDM4E | |
| SCHEMBL13461301 | 0.86 | KMT2A (0.60) | KMT2ASMPD1PRSS1 | |
| SCHEMBL8465014 | 0.84 | SMPD1 (0.68) | KMT2ASMPD1PRSS1THRBNR1H4 | |
| SCHEMBL3489393 | 0.84 | ALDH1A1 (0.56) | KMT2ASMPD1PRSS1KDM4ECYP1A2 | |
| SCHEMBL6356224 | 0.84 | KMT2A (0.47) | KMT2ASMPD1 | |
| SCHEMBL5200730 | 0.84 | KMT2A (0.73) | KMT2ASMPD1THRBNR1H4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056497-A1 | AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056497-A1 | AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056497-A1 | AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2119702-A1 | AMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-11-18 | — | — | EP | disclosed |
| EP-2119702-A1 | AMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056497-A1 | AMIDE DERIVATIVE | REN, AGTR1, AGTR2 | KMT2A 921/4885SMPD1 1119/4885PRSS1 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.